Patents by Inventor Robert Ryder Bartlett

Robert Ryder Bartlett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceuticals for the treatment of rejection reactions in organ transplantations
    Patent number: 7402601
    Abstract: The use of compound 1 and/or 2 of the formulae and of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: July 22, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventor: Robert Ryder Bartlett
  • Pharmaceuticals for the treatment of rejection reactions in organ transplantations
    Patent number: 6288098
    Abstract: The use compound 1 and/or 2 of the formulae and of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described.
    Type: Grant
    Filed: December 23, 1997
    Date of Patent: September 11, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventor: Robert Ryder Bartlett
  • Arylcycloalkyl derivatives, their production and their use
    Patent number: 6159988
    Abstract: Compounds of formula I, ##STR1## and the physiologically tolerable salts thereof, wherein the substituents R.sub.1 -R.sub.4 have the meanings given in the specifications and show an activity against inflammatory conditions.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: December 12, 2000
    Assignee: Hoeschst Aktiengesellschaft
    Inventors: Ramachandra Ganapati Naik, Vilas Narayan Mumbaikar, Ravishankar Vasumathy, Aftab Dawoodbhai Lakdawala, Mandakini Bipin Alreja, Bansi Lal, Jurgen Blumbach, Klaus Ulrich Weithmann, Robert Ryder Bartlett, Kalpana Sanjay Joshi, Swati Bal-Tembe, Sadagopan Raghavan
  • Pharmaceuticals for the treatment of rejection reactions in organ transplantations
    Patent number: 6133301
    Abstract: The use of compound 1 and/or 2 of the formulae ##STR1## and of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: October 17, 2000
    Assignee: Aventis Pharma Deutschland GmbH
    Inventor: Robert Ryder Bartlett
  • 3, 5-disubstituted and 3, 4, 5-trisubstituted 2-isoxazolines and isoxazoles, process for their preparation and their use as pharmaceuticals
    Patent number: 5814627
    Abstract: A compound having the formula (I), a physiologically tolerable salt of the compound having the formula (I) and/or a steroisomeric form of the compound having the formula (I), in which one residue R.sup.1 or R.sup.2 stands for the formula (II), are suitable for preparing medicaments for the therapy of inflammations, asthma, rheumatoid diseases and auto-immune diseases.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: September 29, 1998
    Assignee: Hoechst Aktienegesellschaft
    Inventors: Wilfried Schwab, Hiristo Anagnostopulos, Robert Ryder Bartlett, Rudolf Schleyerbach, Klaus Ulrich Weithmann
  • Arylcycloalkyl derivatives, their production and their use
    Patent number: 5776977
    Abstract: Compounds of formula I, ##STR1## wherein the substituents R.sub.1 -R.sub.4 and a have the given meanings and show an activity against inflammatory conditions.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: July 7, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Ramachandra Ganapati Naik, Vilas Narayan Mumbaikar, Rangarajan Vasumathy, Aftab Dawoodbhai Lakdawala, Mandakini Vithalrao Shirole, Bansi Lal, Jurgen Blumbach, Klaus Ulrich Weithmann, Robert Ryder Bartlett
  • Medicinal use of n-phenyl-2-cyano-3-hydroxycrotonamide derivatives
    Patent number: 5773470
    Abstract: N-Phenyl-2-cyano-3-hydroxycrotonamide derivatives and their use as pharmaceuticals having an immunomodulatory property.The use of N-phenyl-2-cyano-3-hydroxycrotonamide derivatives of the formula I ##STR1## in which R.sup.1 is a hydrogen atom or (C.sub.1 -C.sub.4)-alkyl, R.sup.2 is CN, CX.sub.3, WCX.sub.3, W(CH.sub.2).sub.n CX.sub.3, NO.sub.2, (CH.sub.2).sub.n CX.sub.3, or halogen, in which X is halogen, W is an oxygen or sulfur atom and n is an integer from 1 to 3, R.sup.3 is (C.sub.1 -C.sub.4)-alkyl, (C.sub.3 -C.sub.6)-cycloalkyl, CN or --CO--R.sup.4, in which R.sup.4 is (C.sub.1 -C.sub.4)-alkyl or (C.sub.3 -C.sub.6)-cycloalkyl, and/or their physiologically tolerable salts, for the treatment of rheumatic diseases, autoimmune diseases, and of rejection reactions of the organ recipient to the transplanted organ, is described.
    Type: Grant
    Filed: July 29, 1997
    Date of Patent: June 30, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Rudolf Schleyerbach, Robert Ryder Bartlett, Elizabeth Anne Kuo, Edward James Little
  • N-Phenyl-2-cyano-3-hydroxycrotonamide derivatives
    Patent number: 5747664
    Abstract: The use of N-phenyl-2-cyano-3-hydroxycrotonamide derivatives of the formula I ##STR1## in which R.sup.1 is a hydrogen atom or (C.sub.1 -C.sub.4)-alkyl, R.sup.2 is CN, CX.sub.3, WCX.sub.3, W(CH.sub.2).sub.n CX.sub.3, NO.sub.2, (CH.sub.2).sub.n CX.sub.3, or halogen, in which X is halogen, W is an oxygen or sulfur atom and n is an integer from 1 to 3, R.sup.3 is (C.sub.1 -C.sub.4)-alkyl, (C.sub.3 -C.sub.6)-cycloalkyl, CN or --CO--R.sup.4, in which R.sup.4 is (C.sub.1 -C.sub.4)-alkyl or (C.sub.3 -C.sub.6)-cycloalkyl, and/or their physiologically tolerable salts, for the treatment of rheumatic diseases, auto-immune diseases, and of rejection reactions of the organ recipient to the transplanted organ, is described.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: May 5, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Rudolf Schleyerbach, Robert Ryder Bartlett, Elizabeth Anne Kuo, Edward James Little
  • Pharmaceuticals for the treatment of rejection reactions in organ transplantations
    Patent number: 5728721
    Abstract: The use of compound 1 and/or 2 of the formulae ##STR1## and of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described.
    Type: Grant
    Filed: August 20, 1992
    Date of Patent: March 17, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventor: Robert Ryder Bartlett